Quench Bio, a company leveraging new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, today announced the completion of a $50 million Series A financing led by RA Capital Management ("RA Capital"), with participation from new Investor Abbvie Ventures. Atlas Venture ("Atlas") and Arix Bioscience plc ("Arix", LSE: ARIX) … [Read more...] about Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases